The UCSD CFAR Clinical Investigation Core promotes translational, epidemiologic, and outcomes researchin HIV disease by providing access to an established and successful infrastructure. The objectives of theCore are as follows: (1) provide the services, expertise, and environment necessary for clinicalinvestigation and translational research; (2) provide access to a longitudinal database for epidemiologic,behavioral, and outcomes research; (3) foster communication and collaboration between basic and clinicalinvestigators in academics and industry; (4) support training of junior HIV investigators and education ofmedical personnel; and (5) provide education and awareness of HIV-related research opportunities andCFAR research findings to all HIV-infected individuals, including women and minorities. To meet theseobjectives, the resources of a large, well-established clinical trials unit are made accessible to a broadrange of clinical investigators for pilot and funded projects.Physicians, basic scientists, pharmacists, fellows, junior faculty, and students use Core services. The Corehas also processed requests from academic institutions outside UCSD. The Core provides a full range ofservices, including patient outreach and recruitment; specimen collection; data collection, entry, andanalysis; trial design consultation; training of clinical research personnel; and access to a longitudinal,5,000-patient database containing cumulative clinical, behavioral, and laboratory indicators forepidemiologic- and outcomes-related research. In addition, the Core Directors and affiliated experiencedinvestigators mentor junior investigators and participate in CFAR didactic courses in clinical researchmethods and biostatistics.The opportunities for outcomes and translational work have been expanded with the CNICS (CFARNetwork of Integrated Clinical Systems) project, a collaboration of seven CFAR sites with electronicmedical records databases. Core personnel have facilitated the addition of resistance data to the CNICScohort. In addition, the Core supports an extensive community outreach and education program, whichincludes concerted efforts to reach women, minorities, and injection drug users.CFAR support of the Clinical Investigation Core has enabled the development of new funded programs,scientific collaborations, and numerous abstracts and publications. Future plans include (1) expandingoutcome, resistance and translational research through the CNICS collaboration; (2) expanding the Core'scurrent database to include patient-based measures and enhanced quality assurance of data elements;and (3) fostering multidisciplinary research in the many complications and co-infections that accompany

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-15
Application #
7635789
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2008-06-01
Project End
2012-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
15
Fiscal Year
2008
Total Cost
$224,224
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Blumenthal, Jill; Jain, Sonia; Mulvihill, Evan et al. (2018) Perceived versus calculated HIV risk: Implications for Pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men. J Acquir Immune Defic Syndr :
Naticchia, Matthew R; Laubach, Logan K; Tota, Ember M et al. (2018) Embryonic Stem Cell Engineering with a Glycomimetic FGF2/BMP4 Co-Receptor Drives Mesodermal Differentiation in a Three-Dimensional Culture. ACS Chem Biol 13:2880-2887
Wagner, Karla D; Syvertsen, Jennifer L; Verdugo, Silvia R et al. (2018) A mixed methods study of the social support networks of female sex workers and their primary noncommercial male partners in Tijuana, Mexico. J Mix Methods Res 12:437-457
Bastos, Francisco I; Bastos, Leonardo Soares; Coutinho, Carolina et al. (2018) HIV, HCV, HBV, and syphilis among transgender women from Brazil: Assessing different methods to adjust infection rates of a hard-to-reach, sparse population. Medicine (Baltimore) 97:S16-S24
Kardava, Lela; Sohn, Haewon; Youn, Christine et al. (2018) IgG3 regulates tissue-like memory B cells in HIV-infected individuals. Nat Immunol 19:1001-1012
Namazi, Golnaz; Fajnzylber, Jesse M; Aga, Evgenia et al. (2018) The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis 218:1954-1963
Lada, Steven M; Huang, Karissa; VanBelzen, D Jake et al. (2018) Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. J Clin Microbiol 56:
Cepeda, Javier A; Eritsyan, Ksenia; Vickerman, Peter et al. (2018) Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV 5:e578-e587
Skaathun, Britt; Voisin, Dexter R; Cornwell, Benjamin et al. (2018) A Longitudinal Examination of Factors Associated with Network Bridging Among YMSM: Implications for HIV Prevention. AIDS Behav :
Stone, Jack; Fraser, Hannah; Lim, Aaron G et al. (2018) Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis 18:1397-1409

Showing the most recent 10 out of 921 publications